Email has become an essential business tool across pharmaceutical, biotechnology, medical device, clinical research, and regulatory organizations. Teams use email to communicate development decisions, exchange study information, coordinate quality activities, document approvals, and support regulatory submissions. However, convenience does not make email automatically compliant. When an email becomes part of a regulated record, its integrity, security, retention, accessibility, and appropriate use can become important from an FDA compliance perspective. FDA’s current position on electronic records emphasizes that regulated electronic information must remain trustworthy, reliable, and appropriately controlled. For FDA-regulated organizations, the objective should not simply be to restrict email. Instead, companies should establish a risk-based email governance framework that identifies which communications may constitute regulated records, how those records are controlled, who can access them, and how long they must be retained. The following five practices can help organizations strengthen their FDA email compliance strategy while reducing avoidable regulatory and operational risks.

1. Establish a clear, risk-based email policy. A strong policy is the foundation of effective email management in regulated industry. Organizations should define acceptable uses of corporate email, prohibited activities, responsibilities for employees, rules for external communications, and requirements for handling regulated information. The policy should also address email use through laptops, mobile devices, home networks, public Wi-Fi, and other remote-access environments. FDA does not impose a single universal “email policy” for every regulated company; rather, applicable requirements depend on the records and activities involved. A documented risk assessment can therefore help determine where additional controls are necessary.

2. Determine when emails become regulated records. Not every email is automatically an FDA record. The critical question is whether the communication is created, maintained, or relied upon as part of an activity subject to applicable FDA recordkeeping requirements. Under 21 CFR Part 11, electronic records covered by predicate rules can fall within Part 11 when maintained electronically, and electronic signatures may be subject to Part 11 requirements. FDA recommends determining whether specific records are Part 11 records and documenting that decision. For pharmaceutical and biotech companies, this may intersect with GMP electronic records, quality investigations, manufacturing decisions, laboratory activities, and other controlled processes. Clinical organizations should similarly consider communications that support trial conduct, oversight, or required documentation.

3. Protect confidentiality, security, and data integrity. Email can create significant risks when sensitive information is transmitted through uncontrolled accounts, personal devices, unsecured networks, or inappropriate recipients. Organizations should implement appropriate access controls, authentication, encryption where warranted, malware protection, mobile-device controls, and procedures for reporting misdirected or compromised messages. FDA’s data integrity expectations emphasize that data should be reliable and accurate and that firms should implement meaningful, risk-based controls to prevent and detect integrity problems. For clinical research, this is particularly relevant when emails contain participant-related information, study documentation, or information that could influence trial conduct.

4. Control retention, archiving, and retrieval. An email that supports a regulated decision should not disappear simply because an employee deletes it from an inbox. Companies should establish procedures for FDA record retention, archiving, retrieval, and disposition based on applicable regulatory and business requirements. Retention controls should address both the content of a communication and its associated context, such as attachments and relevant metadata, where necessary. FDA’s Part 11 guidance explains that electronic records maintained under applicable predicate rules need appropriate controls and that organizations should determine in advance whether they will rely on electronic or paper records for regulated activities. A practical retention program should therefore be integrated with the company’s broader document and records management system rather than treated as an isolated IT function.

5. Train employees and routinely test the system. Even sophisticated technology cannot compensate for poor user practices. Employees should receive role-based training on email etiquette, confidential information, attachments, recipient verification, remote access, suspicious messages, record handling, and escalation procedures. Training should extend beyond office-based employees to contractors, clinical personnel, regulatory teams, quality staff, and other individuals who communicate electronically on behalf of the organization. Organizations should also periodically review their controls through internal audits, simulated incidents, access reviews, and inspection-readiness exercises. FDA’s 2024 guidance on electronic systems, electronic records, and electronic signatures in clinical investigations reinforces the importance of trustworthy and reliable electronic systems and records for sponsors, investigators, IRBs, and CROs.

The consequences of weak email controls can extend beyond cybersecurity. Poorly managed communications may create inconsistent records, unexplained decisions, missing documentation, confidentiality concerns, or difficulties demonstrating what happened during an inspection. In a regulated environment, an informal email exchange can sometimes provide important evidence about decision-making, quality events, clinical activities, or regulatory actions. The practical lesson is that organizations should manage email according to its regulatory significance rather than assuming that email is merely a communication channel. Recent FDA emphasis on electronic systems, data integrity, and risk-based controls makes this approach increasingly important. Part 11 remains in effect, while FDA continues to distinguish between records that fall within its scope and electronic information that does not. The Agency also continues to emphasize reliable data and appropriate controls rather than imposing unnecessary technology burdens. For companies operating across multiple functions, this means email governance should be aligned with quality systems, cybersecurity, records management, clinical operations, and regulatory compliance.